Sponsor	Study Name and Link
Akebia	A 36-Week, Single-Group, Open-Label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children with Hyperphosphatemia Related to Chronic Kidney Disease.
Akebia	A 24-Week, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children with Iron Deficiency Anemia Associated with Non-Dialysis Dependent Chronic Kidney Disease. (ClinicalTrials.gov link pending)
Astra Zeneca	A Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Doses of Sodium Zirconium Cyclosilicate (SZC) for Correction of Hyperkalaemia and Effectiveness of Same Dose to Maintain Normokalaemia.
Relypsa	Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)
Roche	Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
Rockwell	Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)